title: Evaluation of micronucleus induction in lymphocytes of patients following boron-neutron-capture-therapy: a comparison with thyroid cancer patients treated with radioiodine.
abstract: This study evaluated micronuclei induction in peripheral T-lymphocytes after BNCT (boron neutron capture therapy) irradiation of 15 brain tumor and 20 head-and-neck cancer patients. In all of these patients, the micronucleus frequency increased after BNCT; the number of micronuclei per 1000 binucleated T-lymphocytes after BNCT increased by 33.0 +/- 12.2 for brain tumor patients and 22.8 +/- 10.3 for head-and-neck cancer patients. In 14 thyroid cancer patients who were administered radioiodine (3.3-5.6 GBq) treatment, the frequency of micronuclei after internal radioiodine therapy increased to 105.0 +/- 30.5 per 1000 binucleated T-lymphocytes. The increased micronucleus frequency of BNCT patients was less than one-third that seen for thyroid cancer patients after radioiodine treatment. These results demonstrate the usefulness of BNCT for selective high-LET radiotherapy, in association with a low irradiation effect of cytological radiation damage after BNCT, which provides a high tumor target dose for each cancer patient.
authors.affiliation: Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan. kinashi@rri.kyoto-u.ac.jp
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kinashi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sakurai
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Masunaga
authors.forename: Minoru
authors.initials: M
authors.lastname: Suzuki
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagata
authors.forename: Koji
authors.initials: K
authors.lastname: Ono
mesh_terms: D016754:Boron Neutron Capture Therapy / Q000009:adverse effects*; D002478:Cells, Cultured; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000145:classification*; D008875:Middle Aged; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000473:pathology / Q000528:radiation effects*; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals